PharmAust's new CEO on his journey in biotech and vision for the company
PharmAust (ASX: PAA) chief executive officer Michael Thurn joins Small Caps to discuss his appointment to the company and recent trial developments.
OUR COMPANY
PAA is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs, lowering the risks and costs of development.
OUR SCIENCE
Monepantel is a potent small molecule drug that has been shown to modulate the mTOR pathway, which plays a pivotal role in driving many cancers.
